Clinical and Genomic Factors Associated with Greater Tumor Mutational Burden in Prostate Cancer

Tumor mutational burden (TMB) is a biomarker that predicts response to immune checkpoint inhibitor therapy. We currently lack a comprehensive understanding of how genomic and clinical factors correlate with TMB. We used a clinicogenomic database to assess independent predictors of TMB levels. The st...

Descripción completa

Detalles Bibliográficos
Autores principales: Hougen, Helen Y., Graf, Ryon P., Li, Gerald, Quintanilha, Julia C.F., Lin, Douglas I., Ross, Jeffrey S., Punnen, Sanoj, Mahal, Brandon A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470357/
https://www.ncbi.nlm.nih.gov/pubmed/37662703
http://dx.doi.org/10.1016/j.euros.2023.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470357/
https://www.ncbi.nlm.nih.gov/pubmed/37662703
http://dx.doi.org/10.1016/j.euros.2023.08.001

Ejemplares similares